logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Four-month high-dose rifampicin regimens for pulmonary tuberculosis

Jindani A, Atwine D, Grint D, Bah B, Adams J,  et al.
2023-09-01 • NEJM Evidence
2023-09-01 • NEJM Evidence
BACKGROUND
Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid a...
Journal Article
|
Research

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Journal Article
|
Review

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry J,  et al.
2019-02-01 • Lancet Gastroenterology and Hepatology
2019-02-01 • Lancet Gastroenterology and Hepatology
Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such a...
Journal Article
|
Research

From Risk to Care: The Hepatitis C Screening and Diagnostic Cascade in a Primary Health Care Clinic in Karachi, Pakistan—a Cohort Study

Khalid GG, Kyaw KWY, Bousquet C, Auat R, Dmytro Donchuk,  et al.
2018-12-28 • International Health
2018-12-28 • International Health
Background In the high-prevalence setting of Pakistan, screening, diagnosis and treatment services for chronic hepatitis C (CHC) patients are commonly offered in specialized facilities. ...
Journal Article
|
Research

Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis

Lim AG, Walker JG, Mafirakureva N, Khalid GG, Qureshi H,  et al.
2020-03-01 • Lancet Global Health
2020-03-01 • Lancet Global Health
BACKGROUND
The WHO elimination strategy for hepatitis C virus advocates scaling up screening and treatment to reduce global hepatitis C incidence by 80% by 2030, but little is known ...
Journal Article
|
Research

Management of Chronic Hepatitis C at a Primary Health Clinic in the High-Burden Context of Karachi, Pakistan

Capileno YA, Van der Bergh R, Donchunk D, Hinderaker SG, Hamid SS,  et al.
2017-04-27 • PLOS One
2017-04-27 • PLOS One
The burden of hepatitis C (HCV) infection in Pakistan is among the highest in the world, with a reported national HCV prevalence of 6.7% in 2014. In specific populations, such as in urba...
Journal Article
|
Letter

Disparity in market prices for hepatitis C virus direct-acting drugs

Andrieux-Meyer I, Cohn J, de Araujo ES, Hamid SS
2015-11-01 • Lancet Global Health
2015-11-01 • Lancet Global Health